相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler et al.
CLINICAL CANCER RESEARCH (2022)
Treatment of Advanced Melanoma in 2020 and Beyond
Russell W. Jenkins et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Ruijuan Du et al.
MOLECULAR CANCER (2021)
Current Melanoma Treatments: Where Do We Stand?
Alvaro Moreira et al.
CANCERS (2021)
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer
Fabiana Alejandra Rossi et al.
ONCOGENESIS (2021)
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
Arwa Alkaraki et al.
CANCERS (2021)
Recent Advances in the Treatment of Melanoma
Brendan D. Curti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
Alejandro Garcia-Alvarez et al.
ONCOTARGETS AND THERAPY (2021)
An update on the implications of cyclin D1 in melanomas
Lucia Gonzalez-Ruiz et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
A20 promotes melanoma progression via the activation of Akt pathway
Jinyuan Ma et al.
CELL DEATH & DISEASE (2020)
The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies
Jennifer E. L. Diaz et al.
ELIFE (2020)
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation
Shensi Shen et al.
CELL REPORTS (2020)
ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma
Ewa Aladowicz et al.
CANCERS (2020)
The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor
Martuza Sarwar et al.
ONCOGENE (2019)
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
Christiane Margue et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes
Esmee Koedoot et al.
NATURE COMMUNICATIONS (2019)
Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival
Nishanth Ulhas Nair et al.
SCIENTIFIC REPORTS (2019)
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Chune Yu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy
Jean Christopher Chamcheu et al.
CELLS (2019)
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Andrea Aloia et al.
CLINICAL CANCER RESEARCH (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities
Aleksandra Simiczyjew et al.
FRONTIERS IN PHARMACOLOGY (2019)
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A. de Weger et al.
BRITISH JOURNAL OF CANCER (2019)
NTRK1 is a positive regulator of YAP oncogenic function
Xinyuan Yang et al.
ONCOGENE (2019)
An RNAi screen of Rho signalling networks identifies RhoH as a regulator of Rac1 in prostate cancer cell migration
Virginia Tajadura-Ortega et al.
BMC BIOLOGY (2018)
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow et al.
CELL (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
Anthony W. Tolcher et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma
Xiaoyang Li et al.
CELL DEATH & DISEASE (2018)
Evaluation of Drug Combination Effect Using a Bliss Independence Dose-Response Surface Model
Qin Liu et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2018)
AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy
Joan Anton Puig-Butille et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma
C. Worrall et al.
ONCOGENE (2017)
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Adrian Vallejo et al.
NATURE COMMUNICATIONS (2017)
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
Simona Caporali et al.
ONCOTARGET (2017)
Extracellular Hsp90 and TGFβ regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model
Jo-Anne de la Mare et al.
BMC CANCER (2017)
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
Simona Caporali et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Gao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
G. Pathria et al.
CELL DEATH & DISEASE (2016)
AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway
Jichang Wu et al.
ONCOLOGY LETTERS (2016)
A neuronal network of mitochondrial dynamics regulates metastasis
M. Cecilia Caino et al.
NATURE COMMUNICATIONS (2016)
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype
Daniela Bossi et al.
CANCER DISCOVERY (2016)
Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant
Wies van Roosmalen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway
Ge Qin et al.
ONCOTARGET (2015)
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
S. Lindsey Davis et al.
FRONTIERS IN PHARMACOLOGY (2015)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Emilia Caputo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
T-V Do et al.
ONCOGENE (2014)
A Genome-Wide RNAi Screen Identifies FOXO4 as a Metastasis-Suppressor through Counteracting PI3K/AKT Signal Pathway in Prostate Cancer
Bing Su et al.
PLOS ONE (2014)
The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
Lifang Xie et al.
MELANOMA RESEARCH (2013)
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
Daehwan Kim et al.
GENOME BIOLOGY (2013)
Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
Meiou Dai et al.
BREAST CANCER RESEARCH (2013)
Xenome-a tool for classifying reads from xenograft samples
Thomas Conway et al.
BIOINFORMATICS (2012)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
分享论文
